Biohaven's Stock Drops After $150M Offering

Biohaven Limiteds stock drops 7% after announcing $150M public offering. The biopharmaceutical company plans to use funds for general corporate purposes, with J.P. Morgan and Goldman Sachs as book-running managers. Share dilution may impact existing stockholders.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.